Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,123 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (356)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | terminated | Phase 2 | 65 | Novartis PharmaceuticalsINDUSTRY | 3 | May 3, 2017 | clinicaltrials |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | terminated | — | 117 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 28, 2017 |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma | terminated | Phase 2 | 5 | Seoul National University HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01849588 | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | terminated | Phase 4 | 3 | Massachusetts General HospitalOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | terminated | Phase 2 | 3 | Taipei Medical University WanFang HospitalOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | terminated | Phase 2 | 4 | City of Hope Medical CenterOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01405573 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma(BOOST) | terminated | Phase 3 | 35 | National Cancer Institute, NaplesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT02323906 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | terminated | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00576056 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | terminated | Phase 2 | 19 | University of PittsburghOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01163526 | Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies | terminated | — | 13 | Stanford UniversityOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT02319200 | Primary Prevention Hepatocellular Carcinoma by Metformin(METFOVIR) | terminated | Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT00427973 | AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer | terminated | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Stanford UniversityOTHER | 1 | Jul 27, 2016 | clinicaltrials |
| NCT00971126 | Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 3 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT01480817 | Sorafenib VS TACE in HCC Patients With Portal Vein Invasion | terminated | Phase 2 | 2 | Seoul National University HospitalOTHER | 1 | Apr 29, 2016 | clinicaltrials |
| NCT01807156 | Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer | terminated | Phase 2 | 7 | Emory UniversityOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT00582400 | A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver | terminated | Phase 2 | 9 | The University of Texas Medical Branch, GalvestonOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | terminated | Phase 2 | 25 | Gabi Chiorean, MDOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00669136 | Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma | terminated | Phase 1 | 2 | Lisa H. Butterfield, Ph.D.OTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01521780 | Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215) | terminated | Phase 1 | 12 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 2, 2015 | clinicaltrials |
| NCT01108705 | Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment(BRISK-APS) | terminated | Phase 3 | 87 | Bristol-Myers SquibbINDUSTRY | 4 | Oct 12, 2015 | clinicaltrials |
| NCT01239355 | MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy | terminated | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 5, 2015 | clinicaltrials |
| NCT01348503 | Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma | terminated | Phase 1 | 5 | Indiana UniversityOTHER | 1 | Aug 31, 2015 | clinicaltrials |
| NCT01539018 | Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE | terminated | Phase 2 | 77 | Egyptian Society of Liver CancerOTHER | 1 | Aug 5, 2015 | clinicaltrials |
| NCT01686880 | Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver(TRYPHON) | terminated | Phase 2 | 10 | Jules Bordet InstituteOTHER | 1 | Jul 1, 2015 | clinicaltrials |
| NCT02482909 | A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma | terminated | N/A | 68 | Seoul National University HospitalOTHER | 0 | Jun 26, 2015 | clinicaltrials |
| NCT01507740 | Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients | terminated | — | 60 | Medical University InnsbruckOTHER | 1 | Apr 29, 2015 | clinicaltrials |
| NCT01029418 | AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT00081900 | A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care | terminated | Phase 1 / Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 13, 2015 | clinicaltrials |
| NCT01872988 | Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma | terminated | Phase 3 | 320 | Taichung Veterans General HospitalOTHER | 1 | Sep 4, 2014 | clinicaltrials |
| NCT00023946 | BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT01215565 | Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma(Fibrolam) | terminated | Phase 2 | 4 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00763776 | Parenchyma Resection of Cirrhotic Liver by the Clamp Crushing Technique and the Ultrasonic Dissector(SECCI) | terminated | N/A | 27 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 27, 2014 | clinicaltrials |
| NCT01128803 | Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response | terminated | Phase 1 / Phase 2 | 1 | Nantes University HospitalOTHER | 1 | Nov 7, 2013 | clinicaltrials |
| NCT01215838 | MRI of the Liver With Eovist | terminated | — | 4 | University of WashingtonOTHER | 0 | Oct 14, 2013 | clinicaltrials |
| NCT00862082 | Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 14 | Proacta, IncorporatedINDUSTRY | 4 | Aug 23, 2013 | clinicaltrials |
| NCT01466504 | Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin | terminated | — | 4 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 15, 2013 | clinicaltrials |
| NCT00828594 | Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 130 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 11, 2013 | clinicaltrials |
| NCT00405873 | Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003 | terminated | Phase 2 | 73 | Auron Healthcare GmbHINDUSTRY | 1 | Mar 20, 2013 | clinicaltrials |
| NCT00047333 | Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed | terminated | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00699374 | Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer | terminated | Phase 3 | 1,075 | PfizerINDUSTRY | 23 | Jan 14, 2013 | clinicaltrials |
| NCT01071434 | Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors | terminated | — | 5 | Stanford UniversityOTHER | 1 | Dec 7, 2012 | clinicaltrials |
| NCT00966251 | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 2 | CureTech LtdINDUSTRY | 1 | Oct 23, 2012 | clinicaltrials |
| NCT01009593 | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 3 | 1,035 | AbbottINDUSTRY | 29 | Sep 10, 2012 | clinicaltrials |
| NCT00426829 | Proton Therapy and Bevacizumab for Primary Liver Tumors | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00562666 | Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells(ICAR) | terminated | Phase 1 | 2 | Rennes University HospitalOTHER | 1 | Jun 22, 2012 | clinicaltrials |
| NCT00618384 | TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)(SOCRATES) | terminated | Phase 2 | 43 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jun 7, 2012 | clinicaltrials |
| NCT01337492 | Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT) | terminated | Early Phase 1 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 21, 2012 | clinicaltrials |
Data updated 22 days agoSource updated May 3, 2017source: clinicaltrials